MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study
The uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation of clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized prostate cancer. We used a large cohort to validate...
Gespeichert in:
| Veröffentlicht in: | PloS one 2016-11, Vol.11 (11), p.e0165236-e0165236 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0165236 |
|---|---|
| container_issue | 11 |
| container_start_page | e0165236 |
| container_title | PloS one |
| container_volume | 11 |
| creator | Eminaga, Okyaz Wei, Wei Hawley, Sarah J Auman, Heidi Newcomb, Lisa F Simko, Jeff Hurtado-Coll, Antonio Troyer, Dean A Carroll, Peter R Gleave, Martin E Lin, Daniel W Nelson, Peter S Thompson, Ian M True, Lawrence D McKenney, Jesse K Feng, Ziding Fazli, Ladan Brooks, James D |
| description | The uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation of clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized prostate cancer. We used a large cohort to validate whether MUC1 protein levels measured by immunohistochemistry (IHC) predict aggressive cancer, recurrence and survival outcomes after radical prostatectomy independent of clinical and pathological parameters.
MUC1 IHC was performed on a multi-institutional tissue microarray (TMA) resource including 1,326 men with a median follow-up of 5 years. Associations with clinical and pathological parameters were tested by the Chi-square test and the Wilcoxon rank sum test. Relationships with outcome were assessed with univariable and multivariable Cox proportional hazard models and the Log-rank test.
The presence of MUC1 expression was significantly associated with extracapsular extension and higher Gleason score, but not with seminal vesicle invasion, age, positive surgical margins or pre-operative serum PSA levels. In univariable analyses, positive MUC1 staining was significantly associated with a worse recurrence free survival (RFS) (HR: 1.24, CI 1.03-1.49, P = 0.02), although not with disease specific survival (DSS, P>0.5). On multivariable analyses, the presence of positive surgical margins, extracapsular extension, seminal vesicle invasion, as well as higher pre-operative PSA and increasing Gleason score were independently associated with RFS, while MUC1 expression was not. Positive MUC1 expression was not independently associated with disease specific survival (DSS), but was weakly associated with overall survival (OS).
In our large, rigorously designed validation cohort, MUC1 protein expression was associated with adverse pathological features, although it was not an independent predictor of outcome after radical prostatectomy. |
| doi_str_mv | 10.1371/journal.pone.0165236 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1841157156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A471863865</galeid><doaj_id>oai_doaj_org_article_c8acb3ceaf684fd1a6ee51deabd183eb</doaj_id><sourcerecordid>A471863865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c725t-f99cecb95fea511ddded4e55e2bb5c2111cc5b7704f6dc9058e7662055d389a73</originalsourceid><addsrcrecordid>eNqNk89u1DAQxiMEoqXwBggsISE47BLHsZNwQFqtWlipVStKuVqOPdm48sZb2yndF-C58f5ptUE9VDk4Gv_msz3zTZK8xekYkwJ_uba964QZL20H4xQzmhH2LDnEFclGLEvJ873_g-SV99dpSknJ2MvkICvKnGW4PEz-nl1NMTq-WzrwXtsO1Ss0Wyz6zrbaBytbWMTVxaBHE--t1CKAQn90aNFE3YLzgC5EaK2xcy3RCYjQRymkO3ThrA-RRlPRSXBf0QSd9Sbo0azzQYc-xOOEQZehV6vXyYtGGA9vdutRcnVy_Gv6Y3R6_n02nZyOZJHRMGqqSoKsK9qAoBgrpUDlQClkdU1lhjGWktZFkeYNU7JKaQkFiwWgVJGyEgU5St5vdZfGer4roee4zDGmBaYsErMtoay45kunF8KtuBWabwLWzblwQUsDXJZC1kSCaFiZNwoLBkCxAlErXBKoo9a33Wl9vQAloQtOmIHocKfTLZ_bWx7fllW0jAKfdgLO3vTgA4_dkGCM6MD2m3uzPEtZmj8BJVVBGKM0oh_-Qx8vxI6ai_hW3TU2XlGuRfkkL3DJopfWWuNHqPipaBwZrdnoGB8kfB4kRCbAXZiL3ns-u_z5dPb895D9uMe2IExovTUbl_khmG9BGf3pHTQP_cApX0_WfTX4erL4brJi2rv9Xj4k3Y8S-QctUiDr</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1841157156</pqid></control><display><type>article</type><title>MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Eminaga, Okyaz ; Wei, Wei ; Hawley, Sarah J ; Auman, Heidi ; Newcomb, Lisa F ; Simko, Jeff ; Hurtado-Coll, Antonio ; Troyer, Dean A ; Carroll, Peter R ; Gleave, Martin E ; Lin, Daniel W ; Nelson, Peter S ; Thompson, Ian M ; True, Lawrence D ; McKenney, Jesse K ; Feng, Ziding ; Fazli, Ladan ; Brooks, James D</creator><creatorcontrib>Eminaga, Okyaz ; Wei, Wei ; Hawley, Sarah J ; Auman, Heidi ; Newcomb, Lisa F ; Simko, Jeff ; Hurtado-Coll, Antonio ; Troyer, Dean A ; Carroll, Peter R ; Gleave, Martin E ; Lin, Daniel W ; Nelson, Peter S ; Thompson, Ian M ; True, Lawrence D ; McKenney, Jesse K ; Feng, Ziding ; Fazli, Ladan ; Brooks, James D</creatorcontrib><description>The uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation of clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized prostate cancer. We used a large cohort to validate whether MUC1 protein levels measured by immunohistochemistry (IHC) predict aggressive cancer, recurrence and survival outcomes after radical prostatectomy independent of clinical and pathological parameters.
MUC1 IHC was performed on a multi-institutional tissue microarray (TMA) resource including 1,326 men with a median follow-up of 5 years. Associations with clinical and pathological parameters were tested by the Chi-square test and the Wilcoxon rank sum test. Relationships with outcome were assessed with univariable and multivariable Cox proportional hazard models and the Log-rank test.
The presence of MUC1 expression was significantly associated with extracapsular extension and higher Gleason score, but not with seminal vesicle invasion, age, positive surgical margins or pre-operative serum PSA levels. In univariable analyses, positive MUC1 staining was significantly associated with a worse recurrence free survival (RFS) (HR: 1.24, CI 1.03-1.49, P = 0.02), although not with disease specific survival (DSS, P>0.5). On multivariable analyses, the presence of positive surgical margins, extracapsular extension, seminal vesicle invasion, as well as higher pre-operative PSA and increasing Gleason score were independently associated with RFS, while MUC1 expression was not. Positive MUC1 expression was not independently associated with disease specific survival (DSS), but was weakly associated with overall survival (OS).
In our large, rigorously designed validation cohort, MUC1 protein expression was associated with adverse pathological features, although it was not an independent predictor of outcome after radical prostatectomy.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0165236</identifier><identifier>PMID: 27846218</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Androgens ; Biology and Life Sciences ; Biomarkers ; Cancer ; Cancer research ; Cancer surgery ; Disease-Free Survival ; Humans ; Immunohistochemistry ; Male ; Medical prognosis ; Medicine and Health Sciences ; Metastasis ; Middle Aged ; Mucin-1 - metabolism ; Mucins ; Multivariate Analysis ; Parameters ; Pathology ; Prognosis ; Proportional Hazards Models ; Prostate cancer ; Prostatectomy ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Research and Analysis Methods ; Seminal vesicle ; Statistical models ; Statistical tests ; Surgery ; Survival ; Treatment Outcome ; Urological surgery ; Urology</subject><ispartof>PloS one, 2016-11, Vol.11 (11), p.e0165236-e0165236</ispartof><rights>COPYRIGHT 2016 Public Library of Science</rights><rights>2016 Eminaga et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Eminaga et al 2016 Eminaga et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c725t-f99cecb95fea511ddded4e55e2bb5c2111cc5b7704f6dc9058e7662055d389a73</citedby><cites>FETCH-LOGICAL-c725t-f99cecb95fea511ddded4e55e2bb5c2111cc5b7704f6dc9058e7662055d389a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112958/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112958/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27846218$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eminaga, Okyaz</creatorcontrib><creatorcontrib>Wei, Wei</creatorcontrib><creatorcontrib>Hawley, Sarah J</creatorcontrib><creatorcontrib>Auman, Heidi</creatorcontrib><creatorcontrib>Newcomb, Lisa F</creatorcontrib><creatorcontrib>Simko, Jeff</creatorcontrib><creatorcontrib>Hurtado-Coll, Antonio</creatorcontrib><creatorcontrib>Troyer, Dean A</creatorcontrib><creatorcontrib>Carroll, Peter R</creatorcontrib><creatorcontrib>Gleave, Martin E</creatorcontrib><creatorcontrib>Lin, Daniel W</creatorcontrib><creatorcontrib>Nelson, Peter S</creatorcontrib><creatorcontrib>Thompson, Ian M</creatorcontrib><creatorcontrib>True, Lawrence D</creatorcontrib><creatorcontrib>McKenney, Jesse K</creatorcontrib><creatorcontrib>Feng, Ziding</creatorcontrib><creatorcontrib>Fazli, Ladan</creatorcontrib><creatorcontrib>Brooks, James D</creatorcontrib><title>MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation of clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized prostate cancer. We used a large cohort to validate whether MUC1 protein levels measured by immunohistochemistry (IHC) predict aggressive cancer, recurrence and survival outcomes after radical prostatectomy independent of clinical and pathological parameters.
MUC1 IHC was performed on a multi-institutional tissue microarray (TMA) resource including 1,326 men with a median follow-up of 5 years. Associations with clinical and pathological parameters were tested by the Chi-square test and the Wilcoxon rank sum test. Relationships with outcome were assessed with univariable and multivariable Cox proportional hazard models and the Log-rank test.
The presence of MUC1 expression was significantly associated with extracapsular extension and higher Gleason score, but not with seminal vesicle invasion, age, positive surgical margins or pre-operative serum PSA levels. In univariable analyses, positive MUC1 staining was significantly associated with a worse recurrence free survival (RFS) (HR: 1.24, CI 1.03-1.49, P = 0.02), although not with disease specific survival (DSS, P>0.5). On multivariable analyses, the presence of positive surgical margins, extracapsular extension, seminal vesicle invasion, as well as higher pre-operative PSA and increasing Gleason score were independently associated with RFS, while MUC1 expression was not. Positive MUC1 expression was not independently associated with disease specific survival (DSS), but was weakly associated with overall survival (OS).
In our large, rigorously designed validation cohort, MUC1 protein expression was associated with adverse pathological features, although it was not an independent predictor of outcome after radical prostatectomy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgens</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Cancer surgery</subject><subject>Disease-Free Survival</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine and Health Sciences</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Mucin-1 - metabolism</subject><subject>Mucins</subject><subject>Multivariate Analysis</subject><subject>Parameters</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prostate cancer</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Research and Analysis Methods</subject><subject>Seminal vesicle</subject><subject>Statistical models</subject><subject>Statistical tests</subject><subject>Surgery</subject><subject>Survival</subject><subject>Treatment Outcome</subject><subject>Urological surgery</subject><subject>Urology</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk89u1DAQxiMEoqXwBggsISE47BLHsZNwQFqtWlipVStKuVqOPdm48sZb2yndF-C58f5ptUE9VDk4Gv_msz3zTZK8xekYkwJ_uba964QZL20H4xQzmhH2LDnEFclGLEvJ873_g-SV99dpSknJ2MvkICvKnGW4PEz-nl1NMTq-WzrwXtsO1Ss0Wyz6zrbaBytbWMTVxaBHE--t1CKAQn90aNFE3YLzgC5EaK2xcy3RCYjQRymkO3ThrA-RRlPRSXBf0QSd9Sbo0azzQYc-xOOEQZehV6vXyYtGGA9vdutRcnVy_Gv6Y3R6_n02nZyOZJHRMGqqSoKsK9qAoBgrpUDlQClkdU1lhjGWktZFkeYNU7JKaQkFiwWgVJGyEgU5St5vdZfGer4roee4zDGmBaYsErMtoay45kunF8KtuBWabwLWzblwQUsDXJZC1kSCaFiZNwoLBkCxAlErXBKoo9a33Wl9vQAloQtOmIHocKfTLZ_bWx7fllW0jAKfdgLO3vTgA4_dkGCM6MD2m3uzPEtZmj8BJVVBGKM0oh_-Qx8vxI6ai_hW3TU2XlGuRfkkL3DJopfWWuNHqPipaBwZrdnoGB8kfB4kRCbAXZiL3ns-u_z5dPb895D9uMe2IExovTUbl_khmG9BGf3pHTQP_cApX0_WfTX4erL4brJi2rv9Xj4k3Y8S-QctUiDr</recordid><startdate>20161115</startdate><enddate>20161115</enddate><creator>Eminaga, Okyaz</creator><creator>Wei, Wei</creator><creator>Hawley, Sarah J</creator><creator>Auman, Heidi</creator><creator>Newcomb, Lisa F</creator><creator>Simko, Jeff</creator><creator>Hurtado-Coll, Antonio</creator><creator>Troyer, Dean A</creator><creator>Carroll, Peter R</creator><creator>Gleave, Martin E</creator><creator>Lin, Daniel W</creator><creator>Nelson, Peter S</creator><creator>Thompson, Ian M</creator><creator>True, Lawrence D</creator><creator>McKenney, Jesse K</creator><creator>Feng, Ziding</creator><creator>Fazli, Ladan</creator><creator>Brooks, James D</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20161115</creationdate><title>MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study</title><author>Eminaga, Okyaz ; Wei, Wei ; Hawley, Sarah J ; Auman, Heidi ; Newcomb, Lisa F ; Simko, Jeff ; Hurtado-Coll, Antonio ; Troyer, Dean A ; Carroll, Peter R ; Gleave, Martin E ; Lin, Daniel W ; Nelson, Peter S ; Thompson, Ian M ; True, Lawrence D ; McKenney, Jesse K ; Feng, Ziding ; Fazli, Ladan ; Brooks, James D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c725t-f99cecb95fea511ddded4e55e2bb5c2111cc5b7704f6dc9058e7662055d389a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgens</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Cancer surgery</topic><topic>Disease-Free Survival</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine and Health Sciences</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Mucin-1 - metabolism</topic><topic>Mucins</topic><topic>Multivariate Analysis</topic><topic>Parameters</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prostate cancer</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Research and Analysis Methods</topic><topic>Seminal vesicle</topic><topic>Statistical models</topic><topic>Statistical tests</topic><topic>Surgery</topic><topic>Survival</topic><topic>Treatment Outcome</topic><topic>Urological surgery</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eminaga, Okyaz</creatorcontrib><creatorcontrib>Wei, Wei</creatorcontrib><creatorcontrib>Hawley, Sarah J</creatorcontrib><creatorcontrib>Auman, Heidi</creatorcontrib><creatorcontrib>Newcomb, Lisa F</creatorcontrib><creatorcontrib>Simko, Jeff</creatorcontrib><creatorcontrib>Hurtado-Coll, Antonio</creatorcontrib><creatorcontrib>Troyer, Dean A</creatorcontrib><creatorcontrib>Carroll, Peter R</creatorcontrib><creatorcontrib>Gleave, Martin E</creatorcontrib><creatorcontrib>Lin, Daniel W</creatorcontrib><creatorcontrib>Nelson, Peter S</creatorcontrib><creatorcontrib>Thompson, Ian M</creatorcontrib><creatorcontrib>True, Lawrence D</creatorcontrib><creatorcontrib>McKenney, Jesse K</creatorcontrib><creatorcontrib>Feng, Ziding</creatorcontrib><creatorcontrib>Fazli, Ladan</creatorcontrib><creatorcontrib>Brooks, James D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eminaga, Okyaz</au><au>Wei, Wei</au><au>Hawley, Sarah J</au><au>Auman, Heidi</au><au>Newcomb, Lisa F</au><au>Simko, Jeff</au><au>Hurtado-Coll, Antonio</au><au>Troyer, Dean A</au><au>Carroll, Peter R</au><au>Gleave, Martin E</au><au>Lin, Daniel W</au><au>Nelson, Peter S</au><au>Thompson, Ian M</au><au>True, Lawrence D</au><au>McKenney, Jesse K</au><au>Feng, Ziding</au><au>Fazli, Ladan</au><au>Brooks, James D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2016-11-15</date><risdate>2016</risdate><volume>11</volume><issue>11</issue><spage>e0165236</spage><epage>e0165236</epage><pages>e0165236-e0165236</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation of clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized prostate cancer. We used a large cohort to validate whether MUC1 protein levels measured by immunohistochemistry (IHC) predict aggressive cancer, recurrence and survival outcomes after radical prostatectomy independent of clinical and pathological parameters.
MUC1 IHC was performed on a multi-institutional tissue microarray (TMA) resource including 1,326 men with a median follow-up of 5 years. Associations with clinical and pathological parameters were tested by the Chi-square test and the Wilcoxon rank sum test. Relationships with outcome were assessed with univariable and multivariable Cox proportional hazard models and the Log-rank test.
The presence of MUC1 expression was significantly associated with extracapsular extension and higher Gleason score, but not with seminal vesicle invasion, age, positive surgical margins or pre-operative serum PSA levels. In univariable analyses, positive MUC1 staining was significantly associated with a worse recurrence free survival (RFS) (HR: 1.24, CI 1.03-1.49, P = 0.02), although not with disease specific survival (DSS, P>0.5). On multivariable analyses, the presence of positive surgical margins, extracapsular extension, seminal vesicle invasion, as well as higher pre-operative PSA and increasing Gleason score were independently associated with RFS, while MUC1 expression was not. Positive MUC1 expression was not independently associated with disease specific survival (DSS), but was weakly associated with overall survival (OS).
In our large, rigorously designed validation cohort, MUC1 protein expression was associated with adverse pathological features, although it was not an independent predictor of outcome after radical prostatectomy.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>27846218</pmid><doi>10.1371/journal.pone.0165236</doi><tpages>e0165236</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2016-11, Vol.11 (11), p.e0165236-e0165236 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1841157156 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adult Aged Aged, 80 and over Androgens Biology and Life Sciences Biomarkers Cancer Cancer research Cancer surgery Disease-Free Survival Humans Immunohistochemistry Male Medical prognosis Medicine and Health Sciences Metastasis Middle Aged Mucin-1 - metabolism Mucins Multivariate Analysis Parameters Pathology Prognosis Proportional Hazards Models Prostate cancer Prostatectomy Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Research and Analysis Methods Seminal vesicle Statistical models Statistical tests Surgery Survival Treatment Outcome Urological surgery Urology |
| title | MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T14%3A28%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MUC1%20Expression%20by%20Immunohistochemistry%20Is%20Associated%20with%20Adverse%20Pathologic%20Features%20in%20Prostate%20Cancer:%20A%20Multi-Institutional%20Study&rft.jtitle=PloS%20one&rft.au=Eminaga,%20Okyaz&rft.date=2016-11-15&rft.volume=11&rft.issue=11&rft.spage=e0165236&rft.epage=e0165236&rft.pages=e0165236-e0165236&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0165236&rft_dat=%3Cgale_plos_%3EA471863865%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1841157156&rft_id=info:pmid/27846218&rft_galeid=A471863865&rft_doaj_id=oai_doaj_org_article_c8acb3ceaf684fd1a6ee51deabd183eb&rfr_iscdi=true |